Molecular PsychiatryNeurosciencePeer-reviewed journal article
LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
Chuyu CheniD, Meghan MasottiiD, Nate ShepardiD, Vanessa PromesiD, Giulia TombesiiD, Daniel ArangoiD, Claudia ManzoniiD, Elisa GreggioiD, Sabine HilfikeriD, Yevgenia KozorovitskiyiD, Loukia ParisiadouiD
Abstract
Haloperidol is used to manage psychotic symptoms in several neurological disorders through mechanisms that involve antagonism of dopamine D2 receptors that are highly expressed in the striatum. Significant side effects of haloperidol, known as extrapyramidal symptoms, lead to motor deficits similar to those seen in Parkinsons disease and present a major challenge in clinical settings. The underlying molecular mechanisms responsible for these side effects remain poorly understood. Parkinsons disease-associated LRRK2 kinase has an important role in striatal physiology and a known link to dopamine D2 receptor signaling. Here, we systematically explore convergent signaling of haloperidol and LRRK2 through pharmacological or genetic inhibition of LRRK2 kinase, as well as knock-in mouse models expressing pathogenic mutant LRRK2 with increased kinase activity. Behavioral assays show that LRRK2 kinase inhibition ameliorates haloperidol-induced motor changes in mice. A combination of electrophysiological and anatomical approaches reveals that LRRK2 kinase inhibition interferes with haloperidol-induced changes, specifically in striatal neurons of the indirect pathway. Proteomic studies and targeted intracellular pathway analyses demonstrate that haloperidol induces a similar pattern of intracellular signaling as increased LRRK2 kinase activity. Our study suggests that LRRK2 kinase plays a key role in striatal dopamine D2 receptor signaling underlying the undesirable motor side effects of haloperidol. This work opens up new therapeutic avenues for dopamine-related disorders, such as psychosis, also furthering our understanding of Parkinsons disease pathophysiology. SummaryChen et al. demonstrate that haloperidol mediated changes in the striatal indirect pathway neurons and circuits are linked to Parkinsons disease associated LRRK2. Inhibiting LRRK2 kinase activity ameliorates the motoric side effects of haloperidol, suggesting a potential approach to alleviating the unwanted side effects of antipsychotics.
- Citations
- 8
- FWCI
- 4.27
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Haloperidol-induced immediate early genes in striatopallidal neurons requires the converging action of cAMP/PKA/DARPP-32 and mTOR pathways
Oriane Onimus, Emmanuel Valjent, … Giuseppe Gangarossa·International Journal of Molecular SciencesPeer-reviewed·Oct 1, 2022
- The Mammalian Target of Rapamycin (mTOR) Kinase Mediates Haloperidol-Induced Cataleptic Behavior
Uri Nimrod Ramírez-Jarquín, Neelam Shahani, … Srinivasa Subramaniam·Translational PsychiatryPeer-reviewed·Oct 2, 2020
- Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine dynamics in VPS35 p.D620N knock-in mice
Mengfei Bu, Jordan Follett, … Matthew James Farrer·bioRxiv·May 14, 2023
- Pathogenic LRRK2 R1441C mutation is associated with striatal alterations
Harry S. Xenias, Chuyu Chen, … Loukia Parisiadou·Communications BiologyPeer-reviewed·Nov 10, 2022
- Dopamine 2 receptor ablation from cholinergic neurons attenuates L-DOPA induced dyskinesias.
Santiago Uribe‐Cano, Lauren B. Malave, Andreas H. Kottmann·Frontiers in Aging NeurosciencePeer-reviewed·May 12, 2026
- Sex- and age-dependent control of dopamine function by LRRK2, and rapid reversal of dopamine release deficits in the LRRK2-G2019S knock-in mouse model of Parkinson's Disease.
Christina Gentle, Anusha Kamesh, … Austen J. Milnerwood·bioRxiv·Oct 16, 2026